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Abstract
Background: For most cancers, only a minority of patients have symptoms meeting the National Institute for
Health and Clinical Excellence guidance for urgent referral. For gastro-oesophageal cancers, the ‘alarm’ symptoms of
dysphagia and weight loss are reported by only 32 and 8 % of patients, respectively, and their presence correlates
with advanced-stage disease. Electronic clinical decision-support tools that integrate with clinical computer systems
have been developed for general practice, although uncertainty remains concerning their effectiveness. The
objectives of this trial are to optimise the intervention and establish the acceptability of both the intervention and
randomisation, confirm the suitability and selection of outcome measures, finalise the design for the phase III
definitive trial, and obtain preliminary estimates of the intervention effect.
Methods/design: This is a two-arm, multi-centre, cluster-randomised, controlled phase II trial design, which will
extend over a 16-month period, across 60 general practices within the North East and North Cumbria and the
Eastern Local Clinical Research Network areas. Practices will be randomised to receive either the intervention (the
electronic clinical decision-support tool) or to act as a control (usual care). From these practices, we will recruit 3000
adults who meet the trial eligibility criteria and present to their GP with symptoms suggestive of gastro-
oesophageal cancer. The main measures are the process data, which include the practitioner outcomes, service
outcomes, diagnostic intervals, health economic outcomes, and patient outcomes. One-on-one interviews in a sub-
sample of 30 patient-GP dyads will be undertaken to understand the impact of the use or non-use of the electronic
clinical decision-support tool in the consultation. A further 10–15 GPs will be interviewed to identify and gain an
understanding of the facilitators and constraints influencing implementation of the electronic clinical decision-
support tool in practice.
Discussion: We aim to generate new knowledge on the process measures regarding the use of electronic clinical
decision-support tools in primary care in general and to inform a subsequent definitive phase III trial. Preliminary
data on the impact of the support tool on resource utilisation and health care costs will also be collected.
Trial registration: ISRCTN Registry, ISRCTN12595588.
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Background
For most cancers, only a minority of patients have
symptoms that meet the National Institute for Health
and Clinical Excellence (NICE) guidance for urgent re-
ferral [1, 2]. For gastro-oesophageal (G-O) cancers, the
‘alarm’ symptoms of dysphagia and weight loss are re-
ported by only 32 and 8 % of patients, respectively [3],
and their presence correlates with advanced-stage dis-
ease [4]. Several other symptoms predict G-O cancer
but with absolute risks in the region of 1 %. Not surpris-
ingly, therefore, delays in diagnosis may occur; 25 % of
oesophageal and 36 % of gastric cancer patients visit
their GPs three times or more before diagnosis [5]; only
34 and 23 %, respectively, are referred by the 2-week
wait (2WW) pathway for urgent referral of patients with
suspected cancer; and 22 and 33 %, respectively, present
as emergencies [6].
The primary investigation for G-O cancer is gastros-
copy, whether by 2WW or direct-access referral. One
solution to a diagnostic delay may be to investigate more
patients. General practices in the lowest tertile of the
gastroscopy referral rate (6.2/1000 per annum (p.a.))
have worse outcomes (emergency admissions, 6-month
mortality) than practices in the highest tertile (16.4/1000
p.a.) [7]. Patients 55 years of age and older account for
65 % of all gastroscopies, and the gastroscopy rate in this
age group is 17.5/1000 p.a. [8]. Gastroscopy rates are
much higher in mainland Europe [9], probably contrib-
uting to the observed better survival. However, because
gastroscopy is a costly and invasive procedure, any in-
crease in activity should target those patients most likely
to benefit.
Recent studies, including those by the co-authors, have
provided robust estimates of the risk of several cancers
(including G-O) for the symptomatic patient in primary
care [3, 10–15]. From these, risk-assessment tools
(RATs) have been developed for use in general practice
[16–18]. In a feasibility study, their use was associated
with increases in 2WW referrals, use of investigations,
and new cancer diagnoses [19]. They have now been de-
veloped in an electronic clinical decision support (eCDS)
format by Macmillan Cancer Support using the BMJ-
owned Informatica platform and integrated with some
GP clinical computer systems.
The Macmillan eCDS tool covers six cancer sites (in-
cluding G-O cancer). It utilises either of two diagnostic
algorithms: the first is based on risk-assessment tools
(RAT) [3], and the second, on Qcancer research [18].
Following extensive piloting, this tool was distributed
as a National Awareness and Early Diagnosis Initiative
(NAEDI) project to 500 practices in 15 Cancer Networks
for a pilot period of 9 months), and its usability has been
qualitatively evaluated in an internal report [20]. However,
the evaluation of this project did not examine the impact
of the eCDS in investigations, on GPs and patients in the
consultation, on clinical outcomes, or on the health eco-
nomics of its use.
Despite increasing promotion of the CDS for clin-
ical practice, great uncertainty still exists about its ef-
fectiveness for potential cancer symptoms. One
systematic review has identified the features critical to
success of clinical decision-support interventions [21].
A second review, of computerised (eCDS) systems,
found that they improved practitioner performance in
64 % of the 97 included studies [22], whereas a third
review identified prompt fatigue as a strong reason
for failure of the eCDS [23]. No randomised con-
trolled trial in primary care has reported on the eCDS
for cancer diagnosis.
Important, but unanswered, questions relate to the im-
plementation and cost-effectiveness of the cancer eCDS
in primary care settings, the impact on clinical out-
comes, and utility over time [24]. We propose to study
this using the Macmillan eCDS tool (in its RAT version)
for G-O cancer diagnosis [3] as our exemplar, for the
clinical reasons listed above, for its health-economic and
resource implications, and because G-O cancer has been
the subject of NAEDI public awareness campaigns.
Trial objectives
The objectives of this trial are provided below:
1. To optimise an intervention based on the use of the
G-O cancer eCDS tool, establish its acceptability,
and collect relevant data to inform the design of a
subsequent definitive phase III trial.
2. To obtain preliminary evidence on the effectiveness,
implementation, and cost-effectiveness of the G-O
cancer eCDS tool.
At the end of this phase II trial, we will have optimised
the intervention and established its acceptability [25].
We will have also generated new knowledge on the
process outcomes of the eCDS in primary care and its
impact on resource utilisation and healthcare costs. In a
subsequent phase III trial, we will examine the effect of
the eCDS on G-O cancer stage at diagnosis, on surgical
treatment, and on survival.
Methods/design
Trial design
This is a multi-site, phase II, cluster-randomised controlled
trial (RCT), supported by the North Wales Organisation
for Randomised Trials in Health (NWORTH Clinical Trials
Unit (CTU)). Cluster randomisation is necessary because
the intervention is implemented at the practice level, but
some process measures and all outcomes relate to individ-
ual patients. Patients 55 years and older, presenting to their
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GP with symptoms associated with G-O cancer (NICE
CG17, CG27, NG12), and capable of informed consent
[2, 26, 27] will be recruited from general practices, ini-
tially in the North East and North Cumbria and the
Eastern Local Clinical Research Networks (LCRNs).
Ethics
Ethical approval for this study was granted on 7 November
2014 by the NRES Committee North East - Tyne & Wear
South (reference number 14/NE/1179). The study will fully
comply with NHS Research Governance regulation. All ne-
cessary NHS and Durham University ethical approvals have
been obtained. Informed consent will be obtained from all
participants. Appropriate safety procedures will be followed
by the researcher(s) when interviewing participants. Should
any disclosures requiring action be made, the researchers
will have access to the support of the project team.
Study setting
We will initially use two recruitment centres, in the
North East and North Cumbria and in the Eastern
LCRN areas to maximise population diversity with re-
spect to socioeconomic status and to understand feasi-
bility issues in diverse local health economies. Practices
that have participated in the Macmillan Cancer Support
eCDS initiative [20] and those with incompatible soft-
ware will be excluded (i.e. practices without a SystmOne
Clinical Computer System).
Sample size
This phase II trial is not powered to test specific hypoth-
eses but to provide sufficient process data and enough
participants with G-O cancer to provide estimates of ef-
fect to inform a phase III trial. We will recruit 60 prac-
tices with 1:1 randomisation, allocating 30 to each of the
intervention and control arms. We anticipate that 64 pa-
tients (32 in each arm) who are subsequently diagnosed
with G-O cancer will participate over the 16-month re-
cruitment period, based on the following assumptions:
(1) 17 out of every 1000 people more than 55 years of
age undergo diagnostic gastroscopy for new upper
gastrointestinal (GI) symptoms each year [1]; (2) 2.1 %
[7] to 5.5 % (Trent Cancer Registry, personal communi-
cation) of these will have G-O cancer, depending on the
route of referral (we have assumed 4 %); (3) the average
practice size is 6500, with 28 % of the patients being
older than 55 years of age [28], which implies that 1800
patients in each practice are age 55+; (4) 80 % of those
with the index symptoms will be identifiable through
READ codes (our own experience); and (5) the consent
rate in the study population is 80 %. To illustrate the re-
cruitment requirements, the number of patients with a
new upper GI symptom annually ranges from 28–40/
1000 [29]. Thus, from 30 control practices, we expect
1292–1843 participants, 780 diagnostic gastroscopies,
and 32 patients with G-O cancer.
Inclusion criteria
To be included, patients must be 55 years of age or older
and presenting to the GP with symptoms associated with
G-O cancer [10, 27].
Exclusion criteria
Patients will be excluded according to the following
criteria:
 If they are deemed unable to provide informed consent
 If the patient did not present to a GP with upper GI
symptoms within the week before the search was run
 If a new prescription for a relevant medication has
been made for reasons other than treatment of
upper GI symptoms
 If the patient has had a diagnosis made or
gastroscopy performed through a route that
bypassed the GP.
Practice recruitment
GP practice recruitment will be supported via the Local
Clinical Research Networks (LCRNs), who will approach
practices in the designated geographical regions, favouring
Research Site Initiative (RSI) practices. Recruitment will
focus on RSI practices because these practices have an on-
going commitment to research and, generally, have allo-
cated research nurse time. In practices that do not have
funded research nurse time, a research nurse from the
LCRNs, if possible, may be funded to support the study.
Representatives from the LCRNs or study team will visit
all practices interested in participating and deliver a short
presentation covering the background, aims, and design of
the trial. Patient recruitment will take place over
16 months or until the required number of participants
has been obtained; whichever is shorter.
Practice randomisation
Practices that agree to participate will complete an initial
assessment, sign a practice agreement form and will then
be randomised into one of two conditions: usual diag-
nostic practice (control) and usual diagnostic practice
plus access to the G-O Cancer electronic risk assessment
tool (eRAT) (as the intervention).
Randomisation will be undertaken by the CTU via a
secure, web-based, fully validated, customised system.
The randomisation will be balanced using matched-pair
methodology within region. Pairs of practices within a
region will be presented for randomisation, which will
be randomised on a 1:1 ratio. Practices are randomised
in pairs to maintain allocation concealment.
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Intervention
Intervention practices will be provided with a modi-
fied version of the Macmillan eCDS tool on the BMJ
Informatica platform, which will contain the G-O
cancer eRAT (Fig. 1) embedded within the clinical
system. This provides a drop-down box containing an
interactive risk calculator, which can be opened at the
GP’s discretion during the consultation. It allows add-
itional symptoms to be entered and generates a value for
the risk of a currently undiagnosed G-O cancer. The GP
then decides on further management, which may be clin-
ical review in primary care, referral to a GI specialist, or
direct referral for gastroscopy. The G-O cancer eCDS will
also display an on-screen prompt at the start of a consult-
ation if the relevant symptom(s) with a total risk >2 % has
(have) been entered within the previous 12 months.
Macmillan has undertaken extensive development and has
addressed many of the key issues identified in the system-
atic reviews of eCDS, particularly the problem of prompt
fatigue [23].
A clinician from the research team will also visit
each intervention practice to deliver an implementa-
tion package developed from a review of relevant sys-
tematic reviews from the Cochrane Effective Practice
and Organisation of Care Group, evidence on the bar-
riers to implementation of decision-support tools in
other disease areas, and normalisation process theory.
This will include the same information as the presen-
tation given to all practices by the LCRNs, along with
specific details of how to use the eRAT. Within this,
whilst emphasising the need to use clinical judgement
in all cases, we will provide guidance on how to in-
terpret the output from the eRAT based on the new
NICE guidance for suspected cancer in primary care
[27]. They may then wish to consider referral for pa-
tients who have a calculated risk of 3 % or more,
whilst those with a calculated risk of less than 3 %
may be better managed by review in primary care.
This practice visit will then be supplemented by peer-
to-peer support as required.
Control practices
Patients presenting to the control practices with
upper gastrointestinal (UGI) symptoms will experience
the GP’s usual diagnostic approach. Usual care is be-
ing used as a comparator for this study to help deter-
mine the actual benefits above normal practice. GPs
in both arms of the trial will be offered free access to
the Cancer Research UK-funded Royal College of
General Practitioners (RCGP) online learning module
on cancer diagnosis and to an end-of-study feedback
event accredited for Continuing Professional Develop-
ment (CPD) purposes. Control practices that have or
acquire the Macmillan eCDS tool will be required to
disable the G-O cancer functionalities for the dur-
ation of the trial.
Process and outcome measures
We will examine the following processes relating to the
use of eCDS:
 Practitioner outcomes – the frequency and
sustainability of the use of eRAT, the adherence to
recommendations, and the attitudes to and role of
eCDS
 Service outcomes – referral rates; use of diagnostic
pathways (2WW and direct access gastroscopy,
conversion (proportion of referrals with cancer
diagnosis)) and detection rates (proportion of G-O
cancers referred through these routes); time from
the first consultation to diagnosis with cancer
(diagnostic interval); and the stage of cancer at
diagnosis using the TNM system
 Health economic outcomes based on estimates of
resource use
 Patient outcomes – the acceptability of the use of
eCDS.
We will perform the following tasks to inform the se-
lection of outcome measures and power calculations for
a subsequent Phase III trial:
1) Estimate the standard deviation for continuous
outcomes
2) Estimate the proportions for binary outcomes (e.g. the
proportion of patients referred in the control arm)
3) Estimate the recruitment and consent rates among
those eligible for inclusion
4) Determine the feasibility of data extraction at
follow-up
5) Examine how closely the stage at diagnosis is related
to treatment with curative intent to inform choice of
primary outcome measure.
Data collection procedures
Patient recruitment
Practice administrative staff will use a pre-specified
search string to search their electronic medical records
weekly in order to identify patients who have presented
to a GP within the previous week with qualifying symp-
toms. The records of patients thus identified will be
reviewed by a designated individual (GP or practice re-
search nurse) to determine eligibility to take part in the
study. Administrative staff will post or use Docmail to
send an information pack (consisting of invitation letter,
participant information sheet, consent form and a reply
paid envelope) to eligible patients.
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We will seek consent for access to primary and sec-
ondary care records for follow-up data and for qualita-
tive interviews. Patients who wish to participate will
return their completed consent forms to the research
centre. The researcher will inform the practice if a con-
sent form is received and whether consent was given for
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Fig. 1 Positive predictive values (95 % confidence intervals) for gastro-oesophageal cancer in men and women over 55 years of age for individual risk
markers and for pairs of risk markers in combination. The top figure in each cell is the positive predictive value when both features are present. The
two smaller figures represent the 95 % CIs for the positive predictive value. These have not been calculated when any cell in the 2×2 table was below
5 (invariably this was because too few controls had both features). The yellow shading is for pairs of symptoms with a positive predictive value over 1 %,
the amber shading is when the positive predictive value is above 2.0 %, and the red shading is for positive predictive values above 5.0 %. The cells along
the diagonal relate to the positive predictive value when the same feature has been reported twice. Thus the back pain/back pain intersect is the positive
predictive value for pancreatic cancer when a patient has attended at least twice with back pain
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data to be used in the study. For those who consent to
their data being used in the study, the practice will re-
spond with the date of the index consultation and, in
addition, for those in the intervention arm, will submit
an age group (in 5-year increments of 55–59, 60–64, 65–
69, 70–74, 75–79, 80–84, 85–89, and 90+), the gender,
and whether or not the eRAT was used.
A database of patients identified by the search string
and those invited to participate will be kept by each
practice; this database will be updated on a weekly basis.
Practice administrative staff will identify any patients
who have not responded at 2 weeks after being sent the
invitation. These patients will be sent a reminder letter
using either post or Docmail. Further information on
the process of patient recruitment is provided in Table 1.
Patient consent is not being sought for the use of the
eCDS during the consultation. This is because the eCDS
tool is used at the discretion of the GP to support his/
her clinical decision making. This is consistent with pre-
vious randomised controlled trials of interventions in
primary care [30, 31]. Use of the eCDS will not detri-
mentally affect patient care, as practitioners will still ad-
here to usual clinical guidelines.
Data collection
Academic research staff will visit GP practices every
6 months to extract data on participating patients to
minimise any loss of data resulting from patient transfer
or death. Staff will also visit gastroenterology units to ex-
tract data from secondary care patient records. All par-
ticipants will be followed up for 6 months. Using data
extraction templates, adapted from those developed by
us for previous comparable studies, we will collect the
information shown in Table 2.
Practice level data on direct-to-gastroscopy referral
and conversion rates will also be collected. The East
Midlands Knowledge and Intelligence Team will hold
cancer waiting time data at the practice level on upper
gastrointestinal (GI) 2WW referrals, conversion and de-
tection rates, and emergency presentations.
Nested qualitative study
We will recruit GP/patient dyads at the intervention
study sites to increase our understanding of the impact
of eCDS use or non-use on the consultation. We will
interview, within 6 weeks of consultation, up to 30 pa-
tients for whom the tool has been used for assessment
of their symptoms, or where the tool was not used des-
pite relevant symptoms, to gain a richer understanding
of the impact of the use or non-use of the eCDS on the
consultation. Consent will be sought from patients to be
interviewed as part of the original participation consent
Table 1 Patient recruitment procedures
Step Frequency Person responsible
Patient consults with relevant symptom
Search of computer records to generate list of patients with qualifying symptoms Weekly Practice admin staff
List reviewed for eligibility and exclusions Weekly Practice research nurse
Invitations sent Weekly Practice admin staff
Response from patient received by researcher Researcher
Consent information to practice Weekly Researcher
Date of index consultation identified for each consenting patient sent to researcher Weekly Practice research nurse
Age group, gender, and use of eRAT (Y/N) identified for each consenting patient
in the intervention practices sent to researcher
Weekly Practice research nurse
Reminders sent Weekly Practice admin staff
Table 2 The type of data collection from the two care sites
Primary care data collection
Demographic data
Date of first consultation
Duration of index (first) consultation
Dates of subsequent consultations before referral
Referral in the episode of care – Y/N
Type of referral (2WW; open access gastroscopy; routine out-patient
department; emergency, other)
Date of referral
Co-morbidities
RAT used - Y/N
Date used
Duration of consultation when RAT used
Final diagnosis
Secondary care data collection
Type of referral (2WW; OAG; routine OPD; emergency, other)
Diagnosis
Date of diagnosis
Stage
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form. The research team will screen the patients who
have consented to be interviewed to purposively sample
for eRAT use and non-use. The researcher will also
match consenting patients with their GP to identify GP/
patient dyads.
These GPs will have been provided with information
about the nested qualitative study at the point of practice
recruitment. GPs subsequently selected to take part in an
interview will be contacted by telephone to confirm that
they are willing to be interviewed and to arrange a suitable
date and time for the interview to take place. GPs who are
interested in participating will provide consent to partici-
pate. If these GPs are unable to find the time for a face-to-
face interview, they will be offered the option of a tele-
phone interview. We will undertake semi-structured inter-
views with as many as possible of the GPs matched with
their patients (up to 30).
We will also interview up to a further 10–15 GPs in order
to identify and gain an understanding of the facilitators and
constraints influencing the implementation and use of
eCDS in clinical practice. GPs will be recruited purposively
to sample as widely as possible (gender, age, trainer status,
and frequency of eRAT use) and will include GPs in the
intervention practices who did not use eCDS during the
study. The interview schedule will be based on normalisa-
tion process theory.
At the end of their interview, all GPs will be asked if
they are willing to take part in further interviews by tele-
phone 3 months and 1 year later. If they agree to do so,
they will be contacted after 2 months to confirm that
they are still willing and to arrange a suitable date and
time for the interview to take place.
Data provided by patients will remain confidential and
will not be shared with their GP, and GP data will also
not be shared with patients. Both patients and GPs will
provide written consent prior to interviews commencing.
GPs who are interviewed by telephone will be asked to
provide verbal consent at the beginning of the interview
and also complete a written consent form to be returned
by post. Data will be audio-recorded and transcribed
professionally.
Data analysis
Statistical analysis
Patient throughput will be summarised for the 16-
month recruitment period. For each trial arm, we will
record the (1) number of eligible patients, (2) number of
eligible patients approached to take part in the study, (3)
number of eligible patients that consented/are recruited
to the trial, and (4) number of recruited patients for
whom outcome data are collected.
We will report the percentage of all eligible patients
who are recruited (participation percentage) and the per-
centage of recruited patients for whom outcome data
are collected with 95 % confidence intervals. Separate
reporting of the participation percentage by the trial arm
will help identify any obvious recruitment bias resulting
from randomising the practices before recruiting pa-
tients to the trial. However, we consider the risk of ser-
ious recruitment bias to be low because all eligible
participants from intervention or control practices will
be invited to participate, and this will be done by post
after the index consultation, rather than during the
consultation.
General practices in the intervention and usual-care
arms will be described separately with respect to region
(a factor used to balance the randomisation). Participat-
ing patients will be described separately within each trial
arm with respect to relevant baseline demographic char-
acteristics, using means and standard deviations (or me-
dians and interquartile ranges) for continuous variables
and percentages for categorical variables. No formal
tests of significance will be used for these descriptive
analyses.
It is not a primary objective of the study to obtain de-
finitive estimates of the intervention effect on study out-
comes. However, comparisons between the intervention
and control arms using the intention–treat principle will
be reported as ancillary analyses. A comparison of binary
outcomes will be implemented using marginal logistic
regression models using generalised estimating equa-
tions (GEEs) with information sandwich (‘robust’) esti-
mates of standard error, specifying the correlation
structure as exchangeable. In the case of rare binary
events, the responses will be summarised using percent-
ages only. Comparison of time-to-event outcomes will
be carried out using marginal proportional hazards
models with information sandwich (‘robust’) estimates of
standard error.
Binary outcomes will be reported using a percentage
for each trial arm, an odds ratio for comparing the trial
arms, a 95 % confidence interval, and p-value. Time-to-
event outcomes will be presented as the hazard ratio,
confidence interval, and p-value. Crude estimates of
intervention effect and estimates adjusted for region and
practice size will be presented. The following outcomes
will be compared:
 For all patients
○ Whether the patient is referred (binary)
 For all referred patients
○ Whether the patient is referred via the 2-week
wait pathway (2WW) (binary)
○ Whether patient is referred via the direct-access
pathway (binary)
○ Whether the referred patients were diagnosed
with cancer (conversion – binary outcome)
 For all patients with cancer
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○ Whether the diagnosed patients had been
referred via the 2WW/direct-access pathway
(binary outcome)
 For patients referred via the 2-week wait
○ Cancer conversion rate (binary outcome)
 For patients referred via the direct-access pathway
○ Cancer conversion rate – (binary outcome)
 For patients diagnosed with cancer
○ Stage at diagnosis
○ Treatment with curative intent (binary
outcome),
○ 1-year and 3-year survival
○ Diagnostic interval (time from symptomatic
presentation to cancer diagnosis)
Health economic analyses
First, we will map out the potential impacts of the eRAT
tool from a health economic viewpoint by determining
the places in the clinical pathway where the eRAT may
impact the cost to the NHS and the benefit to patients
(quality-adjusted life year (QALYs)). These will include
the following:
 A change in the GP consultation length and use of
eRATs that may impact GP costs
 A change in the stage at diagnosis and survival
through earlier diagnosis that may impact QALYs
and costs
 A change in the rates of diagnosis via primary care
as opposed to emergency presentation that may
impact diagnosis costs
 A change in the number of persons without cancer
referred to secondary care that may impact
diagnostic costs.
Second, we will estimated health economic outcomes.
A simple health economic model will be developed using
the eRAT impacts mapped out and populated by cost es-
timates obtained from published literature and other
sources. Health economic outcomes generated will in-
clude the 2WW referral and gastroscopy costs associated
with the eRAT; the cost per additional cancer case diag-
nosed; and the cost per emergency presentation avoided.
We will also explore data requirements and possible
modelling approaches for a health economic evaluation
of a definitive trial.
Qualitative analysis
Our analyses will aim to provide a rich understanding of
patient and practitioner views concerning the acceptability
of eCDS use during the consultation and the potential ef-
fects on process, communication, and patient-centredness.
We will use an iterative analytic process that will start near
the beginning of data collection. Once the early findings
have been reviewed, they will underpin the development of
the thematic framework and inform potential adaptations
to the interview schedule. The qualitative dataset will be
fine-coded, and emergent themes will be identified using
thematic analysis with a constant comparative approach
[32] that will be aided by NVivo software. For the initial
dyadic analysis, the experiences, views, and decisional pro-
cesses of patients will be compared to those of their GP.
The dyadic views will also be compared and contrasted
across the dyadic dataset.
For the subsequent analyses of serial interviews with
GPs over 12 months, the experiences, views, and deci-
sional processes of each GP will be compared across
time points, across GPs, and longitudinally to under-
stand the facilitators and constraints influencing the im-
plementation and use of eCDS in clinical practice.
Data and documentation
All data will be kept in accordance with the Data Protection
Act 1998.
A database will be kept within each practice, which
will contain information about patients invited to take
part in this study; research teams will not have access to
this information. The purpose of keeping this informa-
tion is be able to identify non-responders and to exclude
patients who re-consult about their G-O symptoms after
already having been invited to take part in the study.
At Durham University and the University of Cambridge,
all physical data will be stored in locked filing cabinets in
a locked office in a password-protected corridor within
the Wolfson Research Institute in Durham and the
Department of Public Health and Primary Care
respectively.
At both Durham and Cambridge Universities, all data
stored electronically will be pseudo-anonymised and will be
stored on password protected computers on secure servers.
The study team will have access to the final trial
dataset.
Data anonymisation
All participants will be assigned an anonymous partici-
pant code, which will be used to pseudo-anonymise all
data-collection forms. The key will be stored separately
and will only be accessed by the local research team. In-
terviewees will be given a pseudonym, so they remain
anonymous in the reporting of the qualitative data.
All personal data will be securely destroyed at the end
of the study.
Data monitoring
Due to the non-medicinal and low-risk nature of the
trial, a data monitoring committee will not be needed.
The trial steering committee (which consists of an inde-
pendent chair; the three lead applicants (GR, RDN, and
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FMW), the CTU lead (ZH), the trial statistician (OCU),
a patient representative, an independent statistician, and
an independent clinician) will meet every 6 months from
the start of the study and will monitor study progress,
approve a data analysis plan, and will ensure the study
runs in accordance with the protocol and applicable
standard operating procedures. Some members of the
trial steering committee will take responsibility for the
data monitoring and ethics.
The lead applicants will be responsible for communi-
cating important protocol modifications to relevant par-
ties. The trial is subject to the audit arrangements of the
NIHR CRN. These are independent of the funder and
the sponsor.
Incidence of adverse events
An adverse event will be defined as ‘an event that arises
directly from participation in the research’, including com-
plications that occur in the course of investigation. These
will be reported using an adverse event reporting form.
Dissemination policy
For primary publications, the study team will form the basis
of the writing committee and will also advise on any related
publications. Primary publications will include members of
the study team and other co-investigators as named authors
or as part of a group authorship. In general, any related
publications should include the principal investigators, lead
researchers, and statistician as named authors; however, this
is at the discretion of the writing committee.
Discussion
The objectives of this trial are to optimise the intervention
and establish the acceptability of both the intervention
and randomisation, confirm the suitability and selection of
outcome measures, finalise the design for the phase III de-
finitive trial, and obtain preliminary estimates of the inter-
vention effect. These outputs need to be obtained before
conducting a definitive trial, which would determine the
effect on patient outcomes (the stage at diagnosis, treat-
ment with curative intent, 1-year and 3-year survival, and
diagnostic interval), resulting from the introduction of the
eCDS into general practice for suspected G-O cancer.
We will use the Medical Research Council framework
for the design and evaluation of complex interventions
[25, 33, 34]. We are conducting a phase II, exploratory,
cluster-randomised controlled trial to evaluate an eCDS
tool for suspected G-O cancer (the e-RAT [3]).
The use of the eCDS in intervention practices may re-
sult in a change in practice activity levels for gastros-
copy. The direction of effect is uncertain, since any
increase in activity may be offset by fewer unnecessary
referrals. An absolute 10 % increase in gastroscopies in
the intervention arm would constitute an additional 32
gastroscopies in each network area.
Public awareness campaigns for G-O cancer have been
run as part of the Be Clear on Cancer campaign and re-
sulted in an increase in GP consultations and referrals. If
such a campaign runs in either or both of the two re-
cruitment areas during the recruitment period, we will
monitor and describe it.
New NICE guidance on the investigation of possible
cancer was published in July 2015 after the study was
designed and ethical approval was obtained but before
recruitment had begun. The NICE guidance was based
in part upon the research underpinning the eRAT, so
control practices (if they fully adhere to the new guid-
ance) may offer investigative practice closer in nature to
the intervention practices than was expected at the time
of the trial design. Adoption of the NICE guidelines
(NG12) may also occur at different rates between the
different clinical commissioning groups.
This is one of the first trials of eCDS for the early diagno-
sis of symptomatic cancer and will be completed in 2018.
Trial status
Site recruitment commenced in September 2015, and
the trial is ongoing.
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